Biocryst Pharmaceuticals (BCRX) EBITDA Margin (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) reported EBITDA Margin of 461.74% for Q1 2026, down 46190.0% on a YoY basis from N/an in Q1 2025, and down 101.34% quarter-over-quarter from 34568.22% in Q4 2025.
Biocryst Pharmaceuticals (BCRX) EBITDA Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals has reported EBITDA Margin for 17 years, with the latest figure at 461.74% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 46190.0% year-over-year to 461.74%; the trailing twelve-month figure through Mar 2026 stood at 95.75% (down 8520.0% YoY), and the FY2025 full-year result was 30.06%, up 4987.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 461.74%, down from 34568.22% in the prior quarter.
- The five-year high for EBITDA Margin was 34568.22% in Q4 2025, with the low at 461.74% in Q1 2026.
- Historically, EBITDA Margin has averaged 1963.28% across 5 years, with a median of 41.55% in 2023.
- Annual changes were most pronounced in 2025 — EBITDA Margin soared 3458963 bps — and 2026, when it slumped 46190 bps.
- Biocryst Pharmaceuticals' EBITDA Margin stood at 89.78% in 2022, then advanced by 27 bps to 65.52% in 2023, then surged by 67 bps to 21.41% in 2024, then surged by 161526 bps to 34568.22% in 2025, then sank by 101 bps to 461.74% in 2026.
- The last three EBITDA Margin figures came in at 461.74% (Q1 2026), 34568.22% (Q4 2025), and 7.78% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -170.35% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -16.25% |
| 10 | Biocryst Pharmaceuticals | 2.04 Bn | 1.81 Bn | 151.04 Mn | -461.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -461.74% |
| Dec 31, 2025 | 34,568.22% |
| Sep 30, 2025 | 7.78% |
| Jun 30, 2025 | 3.43% |
| Mar 31, 2025 | 0.17% |
| Dec 31, 2024 | -21.41% |
| Sep 30, 2024 | -10.50% |
| Jun 30, 2024 | -11.79% |
| Mar 31, 2024 | -38.75% |
| Dec 31, 2023 | -65.52% |
| Sep 30, 2023 | -41.55% |
| Jun 30, 2023 | -91.19% |
| Mar 31, 2023 | -76.73% |
| Dec 31, 2022 | -89.78% |
| Sep 30, 2022 | -56.22% |
| Jun 30, 2022 | -90.08% |
| Mar 31, 2022 | -148.60% |
| Dec 31, 2021 | -37.57% |
| Sep 30, 2021 | -143.37% |
| Jun 30, 2021 | -86.66% |